Latest news with #EOM
The Hindu
05-07-2025
- The Hindu
Four held for abduction of youth in Thirumangalam
Thirumangalam Police on Saturday arrested four men for allegedly abducting a 21-year old youth as he failed to repay a loan and physically tortured him. According to police, the victim 21, of Namakkal has been undergoing internship programme and staying in Thirumangalam after completion of He borrowed Rs 85,000 from Sanjay on interest to meet personal expenses a few months ago. Sanjay harassed Rahul for non payment of interest. As he was not able to pay his loan and interest back, Sanjay and others abducted Rahul on Wednesday in a car. They also took a television set, his passport and certificates from his they abandoned him. Based on his complaint, police investigated and arrested four suspects who have been identified as Sanjay, 23, of Tiruvannamalai, Dinesh, 22, Sanjiv Kumar, 19, of Mannurpet and Pradeep, 22, of Ambattur. Police also are searching for other accused who are absconding. A car, a bike, certificates, passport and a television set were recovered from them. EOM
Time of India
03-07-2025
- Time of India
Marlin fish pulls fisherman into sea, fisherman goes missing in Visakhapatnam's Anakapalle coast
VISAKHAPATNAM: A 26-year-old fisherman went missing in the sea after a large fish pulled him into sea while fishing in the blue waters (15 nautical miles off Bay of Bengal) in north coastal Andhra Pradesh. The missing person has been identified as Chodapalli Yerayya, a native of Pudimadaka coastal village in Atchutapuram mandal in Anakapalle district. Yerayya went fishing along with three others from Pudimadaka in a motorized boat on Wednesday morning. After sprawling the bait (line fishing method), Yerayya on board was pulling it. However, a large blue marlin (locally known as kommu konam) fish took the bait and Yerayya was unprepared for the force of the fish pulling on the line, resulting in the fish pulling him into the waters and he went missing in the waters. Though the remaining three fishermen on board and other fishermen searched for Yerayya, their efforts proved futile. It is not the first time that such incidents were reported. A few such incidents were reported on the Vizag coast in the past. Such incidents are possible for a large fish to pull a fisherman into the sea. This usually happens when a powerful fish takes the bait and the fisherman is unable to manage the force of the fish pulling on the line, said Joint Director of Fisheries Department, Anakapalle district, G Vijaya. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 월 평균 148만원 부업! 부업 하실 분 찾습니다 메리츠파트너스 더 알아보기 Undo The search for the missing Yerayya is on, she added. It may be recalled fisherman Molli Joganna was impaled by a huge black marlin fish while he was fishing in the Bay of Bengal, off Andhra Pradeh's Anakapalle coast in February 2022. The tragic incident occurred when Jogannawas attacked by the giant marlin, which is one of the most aggressive fishes known and has a spear-like snout. Joganna was a native of Mutyalammapalem coast in Anakapalle district A group of five fishermen on a traditional boat ventured into the Bay of Bengal for fishing (60 nautical miles from the shore). When the fishermen were lifting the net, they observed that the net was heavy, and they struggled to pull the net. Suspecting that something happened in the net, Joganna ventured into the waters to check. The marlin, which weighed around 80 kgs escaped from the net and pierced Joganna's stomach with its sharp snout. Rescue efforts by the other fishermen failed and they brought Joganna's body ashore. The fishermen said that the demand for the Marlin fish (Kommu Konam) is high in the market and at the same time a lot of risk is also while netting the Kommu Konam fish. Unlike other fishes, Marlin fish attack with its sharp snout. The fishermen also said the size of the fish ranges from 50 kgs to 150 kgs. EOM
The Hindu
17-06-2025
- Politics
- The Hindu
When Union Finance Minister personally clarified about GST for traditionally hand-crafted musical instruments
CHENNAI Union Finance Minister Nirmala Sitharaman found time recently to reply to a post on Thanjavur veenas by social media influencers Pavan and Nandhini. M. Com student Subhashini Kannan, who belongs to a family of veena makers from Thanjavur, had expressed concern over rumours that such instruments too would attract GST. 'We don't get much in terms of profit since we have to invest in the wood and other items. It takes atleast 15 days to make one veena. In such a situation, if GST was also imposed it would be a burden for instrument makers,' she said on the video posted by the Instagram handle @inthemoodforsouth. Responding to her concern, Ms. Sitharaman, thanked Instagrammers Nandhini and Pavan for bringing out the cherished tradition of making handcrafted veenas in Thanjavur and how a few families are keeping the tradition alive. 'We are reaching out to the girl who mentioned her plight about GST in the video, as you have mentioned her number.' Further, she added: 'Just for the information of viewers, would like to state, as per the rules, indigenous handmade musical instruments are completely exempt from GST and hence attract zero GST.' The exemption list includes instruments such as sitar, sarasvati veena, mohan veena, nakula veena, thanthi Panai, elathalam among many others,' the Finance Minister explained. Speaking to The Hindu, Ms. Subashini said she was thankful to Ms. Sitharaman for exempting the instrument from GST. 'Someone else also later clarified that veenas don't attract GST. It came as a relief. After the post, we got orders for three veenas,' she said adding that veenas can be bought from ₹24,000 onwards depending on the colour and designs. They are all made using jackfruit wood. EOM
Associated Press
01-06-2025
- Business
- Associated Press
Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 1, 2025-- To address the rising costs of cancer drugs, investigators from The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, explored the impact of engaging a remote clinical pharmacist in reducing the total cost of care (TCOC) within the Enhancing Oncology Model (EOM) from the Centers for Medicare and Medicaid Services (CMS). From July 1, 2023, to December 31, 2024, seven ClinReview pharmacists (CRPs) within five EOM-participating practices in The Network evaluated more than 5,600 patients for medication initiatives. During the same period, The Network had 12 practices in the EOM nationwide, accounting for approximately 50% of all providers participating in the program. A total of 1,271 interventions were identified, with 1,180 accepted. The sum of TCOC reduction amounted to $8,982,235. Six medication initiatives were implemented and the breakdown of each initiative and average TCOC reduction per intervention are shown in the table below and will be presented in a rapid oral presentation at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting: In addition to the six medication initiatives outlined above, the CRPs contributed an additional $1,201,326 in medication savings associated with drug selection. 'With the national cost of cancer care estimated to exceed $245 billion by 2030, this study provides a clear roadmap for oncology practices looking to reduce costs and improve patient outcomes,' said lead author Daniel Kendzierski, PharmD, senior clinical pharmacist, The Network. 'These findings underscore the critical role of pharmacist-driven medication interventions in driving the success of value-based care models in oncology.' Study Methodology Medication initiatives were clinically evaluated and adopted at an individual practice level and included moAB dose rounding, pembrolizumab dose banding, biosimilar TIC to preferred products, use of a preferred PD-1 agent in metastatic NSCLC, decreased upfront usage of long-acting GF in metastatic cancer, and preferred use of zoledronic acid over alternatives. CRPs remotely reviewed oncology treatment orders for cost-savings opportunities, updated eligible treatments per practice protocols, or reviewed with the treating oncologist. Interventions were submitted by the CRPs into a tracking system and marked as an EOM-related intervention. TCOC reduction was calculated using the difference between the CMS allowable for the original treatment ordered and the new order. Other Research at ASCO 2025 Physicians in The Network are affiliated with dozens of studies being presented at ASCO 2025. Their research highlights clinical and operational findings covering key topics such as the impact of AI on care delivery, access to oncology resources for minority patient populations, and patient experiences with novel therapies. 'As cancer care costs continue to escalate, community oncology practices need novel therapies and innovative solutions to deliver high-quality, affordable care,' said Leslie Busby, MD, Pharmacy & Therapeutics Committee chair and incoming chief medical officer, The Network. 'Research presented at this year's ASCO around digital transformation and patient care delivery in community settings highlights the direct impact practices in The Network have on the communities they serve. This research helps inform how we can continue driving value-based care forward and improving cancer care for all oncology patients.' The Network is supported by McKesson, which has an unmatched portfolio of oncology businesses and partners that provide research, insights, technologies, and services that are helping address barriers and improve cancer and specialty care. At ASCO, McKesson-supported businesses including The Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 170 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies, and early-phase studies. Click here for a full list of SCRI-affiliated studies and presentations and here for Ontada-affiliated abstracts. Expert Panel on Precision Medicine in Community Oncology during ASCO 2025 Additionally, McKesson will be participating in a thought leadership panel hosted by Endpoints News on June 4, 2025, at 12:10pm ET, titled, 'The Future is Now: Digital Transformation Unleashes Precision Medicine in Community Oncology.' Click here to register and join the panelists as they share their insights and perspectives on actionable steps and solutions for community oncology practices to seamlessly integrate precision medicine into their care offerings: ### About The US Oncology Network Every day, The US Oncology Network (The Network) helps more than 2,700 independent providers deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure, and support of McKesson Corporation. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere. About McKesson Oncology and Specialty Solutions It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. View source version on CONTACT: Media Contact The US Oncology Network Claire Crye, Communications [email protected] Health on behalf of The US Oncology Network Christine Murphy, Media Relations [email protected] KEYWORD: TEXAS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL PRACTICE MANAGEMENT MANAGED CARE ONCOLOGY SOURCE: The US Oncology Network Copyright Business Wire 2025. PUB: 06/01/2025 08:00 AM/DISC: 06/01/2025 08:01 AM
Business Wire
01-06-2025
- Health
- Business Wire
Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions
THE WOODLANDS, Texas--(BUSINESS WIRE)--To address the rising costs of cancer drugs, investigators from The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, explored the impact of engaging a remote clinical pharmacist in reducing the total cost of care (TCOC) within the Enhancing Oncology Model (EOM) from the Centers for Medicare and Medicaid Services (CMS). From July 1, 2023, to December 31, 2024, seven ClinReview pharmacists (CRPs) within five EOM-participating practices in The Network evaluated more than 5,600 patients for medication initiatives. During the same period, The Network had 12 practices in the EOM nationwide, accounting for approximately 50% of all providers participating in the program. A total of 1,271 interventions were identified, with 1,180 accepted. The sum of TCOC reduction amounted to $8,982,235. Six medication initiatives were implemented and the breakdown of each initiative and average TCOC reduction per intervention are shown in the table below and will be presented in a rapid oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: In addition to the six medication initiatives outlined above, the CRPs contributed an additional $1,201,326 in medication savings associated with drug selection. 'With the national cost of cancer care estimated to exceed $245 billion by 2030, this study provides a clear roadmap for oncology practices looking to reduce costs and improve patient outcomes,' said lead author Daniel Kendzierski, PharmD, senior clinical pharmacist, The Network. 'These findings underscore the critical role of pharmacist-driven medication interventions in driving the success of value-based care models in oncology.' Study Methodology Medication initiatives were clinically evaluated and adopted at an individual practice level and included moAB dose rounding, pembrolizumab dose banding, biosimilar TIC to preferred products, use of a preferred PD-1 agent in metastatic NSCLC, decreased upfront usage of long-acting GF in metastatic cancer, and preferred use of zoledronic acid over alternatives. CRPs remotely reviewed oncology treatment orders for cost-savings opportunities, updated eligible treatments per practice protocols, or reviewed with the treating oncologist. Interventions were submitted by the CRPs into a tracking system and marked as an EOM-related intervention. TCOC reduction was calculated using the difference between the CMS allowable for the original treatment ordered and the new order. Other Research at ASCO 2025 Physicians in The Network are affiliated with dozens of studies being presented at ASCO 2025. Their research highlights clinical and operational findings covering key topics such as the impact of AI on care delivery, access to oncology resources for minority patient populations, and patient experiences with novel therapies. 'As cancer care costs continue to escalate, community oncology practices need novel therapies and innovative solutions to deliver high-quality, affordable care,' said Leslie Busby, MD, Pharmacy & Therapeutics Committee chair and incoming chief medical officer, The Network. 'Research presented at this year's ASCO around digital transformation and patient care delivery in community settings highlights the direct impact practices in The Network have on the communities they serve. This research helps inform how we can continue driving value-based care forward and improving cancer care for all oncology patients.' The Network is supported by McKesson, which has an unmatched portfolio of oncology businesses and partners that provide research, insights, technologies, and services that are helping address barriers and improve cancer and specialty care. At ASCO, McKesson-supported businesses including The Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 170 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies, and early-phase studies. Click here for a full list of SCRI-affiliated studies and presentations and here for Ontada-affiliated abstracts. Expert Panel on Precision Medicine in Community Oncology during ASCO 2025 Additionally, McKesson will be participating in a thought leadership panel hosted by Endpoints News on June 4, 2025, at 12:10pm ET, titled, 'The Future is Now: Digital Transformation Unleashes Precision Medicine in Community Oncology.' Click here to register and join the panelists as they share their insights and perspectives on actionable steps and solutions for community oncology practices to seamlessly integrate precision medicine into their care offerings: Jason Hammonds, chief operating officer, Oncology & Specialty, McKesson Andrew McKenzie, PhD, vice president, Personalized Medicine, SCRI and scientific director of Genospace Eric Lander, MD, oncologist, Minnesota Oncology, a practice in The US Oncology Network Terri Conneran, founder of KRAS Kickers ### About The US Oncology Network Every day, The US Oncology Network (The Network) helps more than 2,700 independent providers deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure, and support of McKesson Corporation. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere. About McKesson Oncology and Specialty Solutions It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture with Sarah Cannon Research Institute. The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers. Ontada ®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care. As a leading distributor of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them. And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines.
